Clinical characteristics, management, and outcomes of dupilumab-induced psoriasis and psoriasiform eruptions: A systematic review
Journal of the American Academy of Dermatology · 2026-08
DOI: 10.1016/j.jaad.2026.08.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Sherilyn Wen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; School of Medicine, Simon Fraser University, Surrey, British Columbia, Canada. Electronic address: cl13@ua…
Zitieren
APA
Wen, S., Bai, J. Q. A., Rao, V., & Liu, C. (2026). Clinical characteristics, management, and outcomes of dupilumab-induced psoriasis and psoriasiform eruptions: A systematic review. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.08.005
Vancouver
Wen S, Bai JQA, Rao V, Liu C. Clinical characteristics, management, and outcomes of dupilumab-induced psoriasis and psoriasiform eruptions: A systematic review. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.08.005
BibTeX
@article{Wen2026,
author = {Wen, Sherilyn and Bai, Jia Qi Adam and Rao, Vinesh and Liu, Chaocheng},
title = {Clinical characteristics, management, and outcomes of dupilumab-induced psoriasis and psoriasiform eruptions: A systematic review},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.08.005}
}
EUVIMED